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Enantiopure Nb-Fmoc-amino alkyl isonitriles and amino acid esters have been employed as building
blocks in Ugi four-component reaction (U-4CR) to yield 1,10-iminodicarboxylated peptidomimetics. By
employing triﬂuoroacetic acid as one of the components, a different outcome has been observed and
rationalized. Ugi products are obtained as triﬂuoroacetamide adducts, which on further reaction under
mild acidic conditions lead to the title compounds. The method has also been proven to be useful for the
preparation of ethyl, benzyl and tert-butyl esters.




Pg= Fmoc, Boc or Z groupsX = Me, Et, Bn or tBu groups
(a) (b)
Fig. 1. Amino acid derived isonitriles.1. Introduction
The isonitrile based MCRs were developed by Passerini (3CR) in
1921 and then by Ugi (4CR) in 1959.1 Isonitriles have divalent na-
ture and their unique reactivity provides C-nucleophiles toward
imines, resulting in nitrilium electrophiles, enables the wide ap-
plications of Passerini and Ugi reactions to produce diverse array of
products in combinatorial chemistry.2 Ugi reaction has been the
widely recognized MCR, since it has larger ﬂexibility toward gen-
eration of small molecules to larger ones, natural products, pep-
tides, heterocycles and other biologically relevant compounds.3 In
Ugi-4CR, an amine, an aldehyde, an isonitrile, and an acid react in
one-pot leading to the synthesis of a linear peptide-like adduct.
Thus, enantiopure isocyano esters4 have been synthesized and
employed as one of the components in several of the MCRs.5 They
have been employed for the synthesis of complex peptides and
peptidomimetics in one-pot.6 Amino acid derived isocyano ester 1a
remains a focus of much attention, because permutation and
combination of new variants would generate a wide variety of
novel type of molecules as desired by the pharmaceutical industry.7
In this context, the use of C-terminal modiﬁed ‘N-protected amino
alkyl isonitriles’ 1b as building blocks in multicomponent reactions339, 09986312937; e-mail
ariccb@gmail.com, hariccb@
All rights reserved.would be of considerable interest in order to obtain various
peptide-like adducts. A thorough literature survey revealed that
only one derivative namely N-Fmoc/Boc-amino ethyl isonitrile had
been synthesized starting from ethylene diamine in a multistep
approach.8 The above isonitrile was employed for one-pot syn-
thesis of peptide nucleic acids (PNAs). With the objective to in-
corporate isonitrile functionality in place of carboxy group of
optically pure amino acids, we have developed a simple protocol for
conversion of carboxylic acid to formamide, followed by de-
hydration to the isocyanide using Burgess reagent (Fig. 1).9Apart from the application of isocyano ester 1a, several studies
have also been made to broaden the scope of enantiopure bi-
functional amino acids/peptides in MCRs.10 Thus, varieties of bi-
ologically active peptidomimetics have been synthesized via Ugi
MCRs by using amino acid derivatives as aldehyde,11 amine12 or
acid component.13 A prominent example for this kind of MCRs is
N. Narendra et al. / Tetrahedron 68 (2012) 1992e2000 1993the condensation of amino acid, isonitrile and aldehyde to obtain O-
acyl amide, which then undergoes nucleophillic attack by the al-
coholic solvent (MeOH) to give 1,10-iminodicarboxylic acid de-























Scheme 1. General reaction mechanism of U-5C-4CR.Recently, several other groups have utilized a similar protocol to
obtain 1,10-iminodicarboxylic acid derivatives,15 which were found
to be potent inhibitors toward angiotensin converting enzymes and
Zn2þ containing endopeptidase and occur in naturally occurring
crown gall tumors and poisonous mushrooms.16 They have also
been widely used as chiral ligands. Interestingly, the U-5C-4CR is
strongly inﬂuenced by the nucleophillic solvents used. To the best
of our knowledge, only MeOH has been explored as a solvent.















3. toluene, 65 oC
4. 98% HCOOH,















Amino acids employed: Gly, Ala, Phe, Asp(β-Bn), Lys(Z), Pro, Ile, Glu (γ-Bn)
Fig. 2. Building blocks employed for U-4CR.Focusing on ﬁnding a new class of 1,10-iminodicarboxylated
peptidomimetics, we employed Nb-Fmoc-protected amino alkyl
isonitrile 1b and amino acid esters. Peptide adducts obtained from
present method are rich in chiral centers and possesses bothN- and
C-termini. Herein to obtain aforementioned peptidomimetics, we
explored U-4CR rather than U-5C-4CR through condensation of
amino acid ester, CF3COOH, isonitrile and aldehyde. The Ugi prod-
ucts 4were obtained as triﬂuoroacetamide adducts, which after the
cleavage of triﬂuoroacetyl group from respective adducts affords
1,10-iminodicarboxylated peptidomimetics 5. In both the steps
a good diastereoselectivity was observed. This work has been
demonstrated not only to obtain new class of peptidomimetics, but
constitutes an alternative to complement the earlier route of U-5C-
4CR involving amino acids providing both amino as well as carboxy
termini.2. Results and discussion
In our approach to obtain the hitherto unreported class of Ugi
peptide adducts, Nb-Fmoc-amino alkyl isonitriles have been syn-thesized following our previous report.9a In a short note, carboxy
group of Nb-Fmoc-amino acids were directly converted to the
corresponding isocyanates through established protocol,9d which
then undergoes DMAP catalyzed formylation with 98% HCOOH.
The formamides were then dehydrated using Burgess reagent
(Fig. 2).
Considering the successful implementation as well as mecha-
nistic studies of Ugi 5C-4CR, we expected that other nucleophilic
solvents (except MeOH) could give rise to a corresponding ester as
Ugi product. In an initial study, N-FmocePhe-j-[CH2NC] wasemployed in Ugi 5C-4CR (Scheme 2). Enantiopure L-Ala in MeOH
was cooled to 30 C, equimolar amounts of benzaldehyde and N-
FmocePhe-j-[CH2NC] were added. Indeed, after 46 h of vigorous
stirring at 30 C, we obtained the Ugi product 2 in 59% yield (Table
1, entry a). But only a slight increase in the yield was observed at
60 C (Table 1, entry b). When the same reaction was performed in
presence of EtOH, the desired product was obtained in 28% yield
(Table 1, entry c) and only 2% was scaled upon reﬂux (Table 1, entry
d). In contrast, replacing EtOH with benzyl alcohol had no result at
room temperature (Table 1, entry e) and about only 5% of the
product was obtained at 70 C (Table 1, entry f). However, the use of
tert-butanol affords a trace amount of Ugi product at 30 C as well
as at 60 C (Table 1, entries g and h). These results are in accordance
with the known observations that nucleophillic solvents drastically

















Scheme 2. Synthesis of 2 via Ugi 5C-3CR using different nucleophillic solvents under various conditions.
Table 1
Results of Ugi 5C-3CR in various solvents from Scheme 2
Entry Solventa X Time (h) Temp (C) Yieldb (%)
a MeOH Me 46 30 59
b MeOH Me 45 60 61
c EtOH Et 58 30 28
d EtOH Et 56 70 30
e BnOH Bn 58 30 d
f BnOH Bn 55 70 05
g t-BuOH t-Bu 50 30 20
h t-BuOH t-Bu 51 60 24
a Ten-fold excess of solvents were taken.
b Yields of the crude products.
N. Narendra et al. / Tetrahedron 68 (2012) 1992e20001994solvents could be expected. This is probably due to steric factors
arising from the cyclic intermediate, which restricts the smooth
nucleophillic attack by the solvent and poor solubility of the amino
acid also.
To circumvent the above drawbacks, it is imperative to choose
an alternative protocol. We might expect that a linear peptide-like
adduct rather than cyclic intermediate can be obtained easily
through U-4CR. While implementing this strategy, selecting strong
acid component ﬁnds an attractive objective. Thus, triﬂuoroacetic
acid (TFA) was chosen as an acid component in our present study.
U-4CR gives linear non cyclic triﬂuoroacetamide adduct as Ugi
product in less duration of time under mild conditions with good
diastereoselectivities (Scheme 3). In the subsequent step, the title
compounds can be obtained after the removal of triﬂuoroacetyl
function under mild acidic condition (Scheme 4).
To examine the above strategy, a typical reaction has been
conducted using HeAlaeOMe as amino component. To a solution of
HeAlaeOMe (hydrochloride salt was deprotonated by treatment





















Scheme 3. Preparation of 1,10-iminodicarboxylated peptidomimetics through U-4CR.
p-TsOH.H2O
MeOH, TEA
























Scheme 4. Deprotection of triﬂuoroacetyl group of Ugi products 4.was added at room temperature, the reaction mixture was allowed
to stir under the same temperature for 2 h to ensure the imine
formation, and then Nb-FmocePhe-j-[CH2NC] and triﬂuoroacetic
acid (TFA) were added. After stirring for another 1 h (monitored byTLC analysis), a simple work-up followed by column puriﬁcation
afforded Ugi product 4c as triﬂuoroacetamide adduct in good yield
(85%, Table 2).
In the ﬁnal step of the study, we carried out cleavage of tri-
ﬂuoroacetyl group of Ugi products 4. For the deprotection, the
widely known base catalyzed cleavage methods employing K2CO3,
Na2CO3 or NH318 are not compatible with Fmoc chemistry. In pur-
suit of an alternative protocol, we followed Li et al., approach which
involves treatment with p-TsOH.19 This method also facilitates the
isolation of product after simple work-up. In the present study
(Scheme 3), Ugi products 4 were treated with p-TsOH in MeOH at
50 C, and the ﬁnal product 5 was formed over 30 min (TLC anal-
ysis). A simple work-up led to the isolation of the desired product 5
in good yields (Table 3). However, due to the acidic nature of the
reaction conditions employed, about 10e15% of tert-butyl ester
cleavage was observed in case of 5j and 5k (Table 3, entries 10
and 11).
The broad utility of the current version of the strategy to syn-
thesize 1,10-iminodicarboxylated derivatives is demonstrated by
studying the feasibility of the protocol using several functionalized
amino acids viz. Ser, Asp(b-Bn), Lys(Z), Glu(g-Bn), Tyr, Cys and Met
either as isonitrile or as an amino component. In all the cases Ugi
peptide adducts 4 were obtained without any difﬁculty and prod-
ucts were obtained in good yield within 2e3 h. In addition, we did
not observe any considerable decrease in the yield, when we used
sterically hindered aldehydes. According to the mechanism of the
Ugi-4CR, a mixture of diastereomeric products was obtained, which
arises from the new chiral center created at the quaternary carbon
of the aldehyde. In addition, both the products 4 and 5 had similar
diastereoselectivities and were not separable in column chroma-
tography, although, HPLC had displayed good selectivity of the
products.3. Conclusion
In conclusion, this report outlines the synthesis of 1,10-imino-
dicarboxylated peptidomimetics. U-4CR was found to be suitable
protocol rather than known U-5C-3CR, provided appropriate acid
component was chosen. Reaction of Nb-Fmoc-amino alkyl iso-
nitriles, amino acid esters, commercially available aldehydes and
triﬂuoroacetic acid affords triﬂuoroacetamide peptidomimetic ad-
ducts in good yield. Further, cleavage of triﬂuoroacetyl functionality
under mild conditions afforded title molecules. An Ugi 4CR usingtriﬂuoroacetic acid as the carboxylic acid component and a per-
formed amino acid ester as the amine component was found to be
preferable to the known U-5C-3CR in involving solvolysis of the
reaction intermediate.
Table 2
Triﬂuoroacetamide possessing Ugi adducts isolated from Scheme 2
Product R1 R2 R3 X Yielda (%) Timeb (h) drc
4a H Ph CH2OH Me 86 1 89:11
4b CH3 H CH2Ph Et 91 3 100:0
4c CH2Ph CH2CH(CH3)2 CH3 Me 85 1 79:21
4d e(CH2)3e H CH2CH(CH3)2 Bn 79 2 100:0
4e CH2Ph Ph CH3 Me 78 1 84:16
4f (CH2)4NHZ Ph CH3 Me 83 2.5 75:25
4g CH2CH(CH3)2 H CH2Ph-pOH Me 89 0.5 100:0
4h CH(CH3)2 C(CH3)3 H Bn 93 1.5 98:2
4i CH2COOBn H CH2CH2SCH3 Et 87 3 100:0
4j CH2CH2COOBn C(CH3)3 CH3 t-Bu 86 1.6 91:9
4k CH(CH3)CH2CH3 CH2CH(CH3)2 CH3 t-Bu 88 3.5 97:3
a Yields of the isolated product.
b Time refers to complete consumption of isonitriles.
c Diastereomeric ratios were established by RP-HPLC analysis of the puriﬁed products.
N. Narendra et al. / Tetrahedron 68 (2012) 1992e2000 19954. Experimental
4.1. General
All amino acids aldehydes were used as obtained from Sigma-
eAldrich Company, USA. Unless or otherwise mentioned, all amino
acids used were of L-conﬁguration. All the solvents were dried and
puriﬁed using recommended procedures in the literature when
necessary. High resolution mass spectra were recorded on
a Micromass Q-TOF micro mass spectrometer using electron spray
ionization mode. IR spectra were recorded on a Schimadzu model
FT-IR spectrometer. 1H NMR and 13C NMR spectra were recorded on
a Bruker AMX 300 MHz and 100 MHz spectrometers, respectively.
19F NMR was recorded on a Bruker AMX 376 MHz (internal stan-
dard CFCl3). Melting points were determined in an open capillary
and are uncorrected. TLC experiments were done using MERCK TLC
aluminum sheets (silica gel 60 F254) and chromatograms were vi-
sualized by exposing in iodine chamber, UV-lamp or spraying with
KMnO4 and heating. Column chromatography was performed on
silica gel (100e200 mesh) using ethyl acetate and hexane mixtures
as eluent.
4.2. Typical procedure for synthesis of 2
To a solution of HeAlaeOH (5.0 mmol, 445.5 mg) in 50 mL of
alcohol (MeOH/EtOH/BnOH/t-BuOH) was cooled to 15 C. N-
FmocePhe-j-[CH2NC] (5.0 mmol, 1.91 g) and benzaldehyde
(5.0 mmol, 0.54 mL) were added. The resulting mixture was
stirred at the indicated temperature and time. The mixture was
then concentrated in vacuo and the crude product was
analyzed.
4.3. General procedure for the synthesis of 4
The triﬂuoroacetic acid (5.0 mmol, 0.683 mL), amino acid ester
(5.1 mmol), and aldehyde (5.1 mmol) were dissolved in MeOH to an
approximate concentration of 1 M each. This solution was then
stirred for 20 min at room temperature, and then Nb-Fmoc-amino
alkyl isonitrile (5.0 mmol) was added in one portion. The resulting
solution was allowed to stir at room temperature for 4 h. When the
reaction was complete by TLC (10% MeOH in CH2Cl2), the solvent
was removed in vacuo, and the residue puriﬁed by column
chromatography.
Note: The spectral characterization data for the compounds
4aek and 5aek corresponding to the major diastereoisomer.
4.3.1. Methyl 2-((2-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)ethyl-
amino)-2-oxo-1-phenylethyl)-2,2,2-triﬂuoroacetamido)-3-
hydroxypropanoate (4a). White solid; mp 138e139 C; Rf 0.54 (n-hexane/EtOAc, 2:1); RP-HPLC tR 21.1, 21.6 (60e100% ACN; 30 min);
[a]D20 þ25.3 (c 1.0, CHCl3); IR (KBr) nmax 3025, 2877, 2568, 1751,
1735, 1635, 1380 cm1; 1H NMR (300 MHz, CDCl3) d 2.74 (br s, 1H,
OH Ser), 3.15 (t, J¼2.9 Hz, 2H, NHCH2CH2), 3.26 (t, J¼4.8 Hz, 2H,
NHCH2CH2), 3.65 (s, 3H, OCH3), 3.89e4.01 (m, 2H, CH2 Ser), 4.42 (t,
J¼5.8 Hz, 1H, CH Fmoc), 4.65 (d, J¼3.6 Hz, 2H, CH2 Fmoc), 4.51 (m,
1H, CH Ser), 5.18 (br, 1H, eNH), 5.32 (s, 1H, CH Ph), 5.83 (br, 1H,
NH), 7.09e7.48 (m, 13H, HAr); 13C NMR (75 MHz, CDCl3) d 38.6,
39.1, 46.2, 50.5, 55.3, 57.4, 57.6, 65.8, 112.6, 124.6, 125.9, 127.2, 127.8,
128.0, 128.2, 128.9, 129.0, 135.4, 141.0, 142.6, 154.8, 155.6, 168.2,
170.2; 19F NMR (376 MHz, CDCl3) d 75.44 (s, 3F, COCF3); HRMS
(ESI) calcd for C31H30F3N3O7 m/z 636.1934 (MþNa)þ, found
636.1912.4.3.2. Ethyl 2-(N-(2-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)propy-
lamino)-2-oxoethyl)-2,2,2-triﬂuoroacetamido)-3-phenylpropanoate
(4b). Pale yellow solid; mp 143e144 C; Rf 0.48 (n-hexane/EtOAc,
2:1); RP-HPLC tR 22.4 (60e100% ACN; 30 min); [a]D20 þ54.6 (c 1.0,
CHCl3); IR (KBr) nmax 3030, 2858, 1755, 1741, 1640, 1311 cm1; 1H
NMR (300 MHz, CDCl3) d 1.12 (d, J¼5.6 Hz, 3H, CH3 Ala), 1.21 (t,
J¼9.1 Hz, 3H, OCH2CH3), 2.96e3.08 (m, 2H, CH2 Phe), 3.11e3.23 (m,
2H, CHCH2NH), 3.96 (s, 2H, NHCOCH2N), 4.11 (m, 2H, OCH2CH3),
4.21 (m, 1H, CH Ala), 4.42 (t, J¼3.9 Hz, 1H, CH Fmoc), 4.65 (d,
J¼4.7 Hz, 2H, CH2 Fmoc), 4.72 (m, 1H, CH Phe), 5.65 (br, 1H, NH),
5.94 (br, 1H, NH), 7.11e7.54 (m,13H, ArH); 13C NMR (75 MHz, CDCl3)
d 13.8, 17.6, 36.2, 45.9, 46.1, 47.3, 49.5, 52.6, 60.4, 67.0, 112.6, 124.8,
124.6, 126.0, 126.8, 127.3, 127.8, 128.3, 138.4, 141.1, 143.2, 154.8,
155.0, 169.4, 170.0; 19F NMR (376 MHz, CDCl3) d 74.37 (s, 3F,
COCF3); HRMS (ESI) calcd for C33H34F3N3O6m/z 648.2297 (MþNa)þ,
found 648.2274.4.3.3. Methyl 2-(N-(1-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-3-
phenylpropylamino)-4-methyl-1-oxopentan-2-yl)-2 ,2 ,2-
triﬂuoroacetamido)propanoate (4c). White solid; mp 123e124 C;
Rf 0.61 (n-hexane/EtOAc, 2:1); RP-HPLC tR 19.6, 19.8 (60e100% ACN;
30 min); [a]D20 þ34.2 (c 1.0, CHCl3); IR (KBr) nmax 3039, 2860, 1755,
1734, 1711, 1639, 1366 cm1; 1H NMR (300 MHz, CDCl3) d 0.96 [d,
J¼3.9 Hz, 6H, CH(CH3)2], 1.42 (d, J¼7.1 Hz, 3H, CH3 Ala), 1.56 [m, 1H,
CH2CH(CH3)2], 1.87 [m, 2H, CH2CH(CH3)2], 2.32e2.41 (m, 2H, CH2
Phe), 3.11e3.19 (m, 2H, CHCH2), 3.62 (s, 3H, OCH3), 4.23 (t, J¼5.6 Hz,
1H, CH Fmoc), 4.31e4.48 (m, 3H, CH i-Bu, CH Ala, CH Phe), 4.58 (d,
J¼3.8 Hz, 2H, CH2 Fmoc), 5.13 (br, 1H, NH), 5.92 (br, 1H, NH),
7.10e7.52 (m,13H, ArH); 13C NMR (75 MHz, CDCl3) d 13.2, 19.6, 20.4,
37.6, 39.1, 43.0, 45.6, 46.8, 48.1, 50.1, 52.2, 65.6, 112.3, 125.8, 126.2,
127.1,127.5, 127.9, 128.3,128.5,137.3, 141.6, 143.0,153.2,155.0,169.8,
170.4; 19F NMR (376 MHz, CDCl3) d 76.13 (s, 3F, COCF3); HRMS
(ESI) calcd for C36H40F3N3O6 m/z 690.2767 (MþNa)þ, found
690.2750.
Table 3
1,10-Iminodicarboxylated peptidomimetics 5 synthesized
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Table 3 (continued )



















a Isolated yield after column puriﬁcation.
b Diastereomeric ratios were determined by RP-HPLC analysis of the puriﬁed products.
N. Narendra et al. / Tetrahedron 68 (2012) 1992e2000 19974.3.4. (9H-Fluoren-9-yl)methyl 2-((2-(N-(1-(benzyloxy)-3-methyl-1-
oxobutan-2-yl)-2,2,2-triﬂuoroacetamido)acetamido)methyl)pyrroli-
dine-1-carboxylate (4d). White solid; mp 181e183 C; Rf 0.11 (n-
hexane/EtOAc, 2:1); RP-HPLC tR 20.1 (60e100% ACN; 30 min);
[a]D20 þ79.2 (c 1.0, CHCl3); IR (KBr) nmax 2859, 1751, 1742, 1710,
1685, 1631, 1399 cm1; 1H NMR (300 MHz, CDCl3) d 0.92 [d,
J¼4.6 Hz, 6H, (CH3)2 Val], 1.32e1.38 (m, 2H, NCHCH2 Pro),
1.41e1.51 (m, 2H, eNCH2CH2 Pro), 3.12e3.26 [m, 4H, NCH2CH2
(Pro), CHCH2], 3.82 (m, 1H, eNCHCH2, Pro), 3.96 (s, 2H,
NHCOCH2N), 4.16 (d, J¼6.9 Hz, 1H, CH Val), 4.42 (t, J¼8.1 Hz, 1H,
CH Fmoc), 4.59 (d, J¼4.6 Hz, 2H, CH2 Fmoc), 5.14 (s, 2H, OCH2Ph),
5.65 (br, 1H, eNH), 7.12e7.39 (m, 13H, ArH); 13C NMR (75 MHz,
CDCl3) d 19.9, 22.8, 26.7, 28.6, 40.2, 45.5, 46.2, 50.0, 55.1, 65.1, 66.1,
66.8, 112.3, 125.9, 126.8, 127.2, 127.5, 128.0, 128.3, 128.9, 139.1,
140.2, 142.2, 154.1, 155.6, 170.0, 170.9; 19F NMR (376 MHz, CDCl3)
d 75.38 (s, 3F, COCF3); HRMS (ESI) calcd for C36H38F3N3O6 m/z
688.2610 (MþNa)þ, found 688.2604.
4.3.5. Methyl 2-(N-(2-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-3-
phenylpropylamino)-2-oxo-1-phenylethyl)-2,2,2-triﬂuoroacetamido)
propanoate (4e). Pale yellow solid; mp 151e152 C; Rf 0.58 (n-
hexane/EtOAc, 2:1); RP-HPLC tR¼23.2, 23.4 (60e100% ACN; 30 min);
[a]D20þ82.4 (c 1.0, CHCl3); IR (KBr) nmax 3038, 2855, 1750, 1739, 1716,
1645, 1377 cm1; 1H NMR (300 MHz, CDCl3) d 1.36 (d, J¼5.8 Hz, 3H,
CH3 Ala), 2.36e2.48 (m, 2H, CH2 Phe), 3.11e3.23 (m, 2H, CHCH2NH),
3.68 (s, 3H, OCH3), 4.31 (t, J¼7.6 Hz, 1H, CH Fmoc), 4.43 (m, 1H, CH
Ala), 4.55 (m, 1H, CH Phe) 4.67 (d, J¼6.8 Hz, 2H, CH2 Fmoc), 5.31 (m,
1H, CH Ph), 5.65 (br, 1H, NH), 5.91 (br, 1H, NH), 7.10e7.48 (m, 18H,
ArH); 13C NMR (75 MHz, CDCl3) d 13.2, 38.6, 43.2, 44.6, 46.1, 50.1,
52.6, 57.2, 66.8, 112.0, 124.8, 125.6, 126.4, 126.8, 127.1, 127.5, 128.0,
128.5,128.9,129.0,135.2, 137.1, 141.0,143.2,154.5,154.8,167.2,170.2;
19F NMR (376 MHz, CDCl3) d 74.91 (s, 3F, COCF3); HRMS (ESI) calcd
for C38H36F3N3O6 m/z 710.2454 (MþNa)þ, found 710.2441.
4.3.6. Methyl 2-(N-(2-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-6-
(benzyloxycarbonyl)hexylamino)-2-oxo-1-phenylethyl)-2,2,2-
triﬂuoroacetamido)propanoate (4f). White solid; mp 171e172 C; Rf
0.21 (n-hexane/EtOAc, 2:1); RP-HPLC tR 18.5, 18.8 (60e100% ACN;
30 min); [a]D20 þ51.2 (c 1.0, CHCl3); IR (KBr) nmax 3020, 2877, 1755,
1745, 1715, 1641, 1369 cm1; 1H NMR (300 MHz, CDCl3) d 1.11e1.15
(m, 2H, NHCHCH2CH2 Lys), 1.21 (d, J¼3.9 Hz, 3H, CH3 Ala), 1.41e1.49
(m, 4H, CH2CH2CH2CH2 Lys), 2.78 (t, J¼9.1 Hz, 2H, CH2 NHZ),
3.09e3.19 (m, 2H, CHCH2NHe), 3.64 (s, 3H, eOCH3), 3.98e4.11 (m,
2H, CH Lys, Ala), 4.38 (t, J¼5.9 Hz, 1H, CH Fmoc), 4.62 (d, J¼2.9 Hz,
2H, CH Fmoc), 5.18 (s, 2H, CH2 Z), 5.22 (m, 1H, CH Ph), 5.81 (br, 1H,NH), 6.12 (br, 1H, NH), 7.12e7.59 (m, 18H, ArH); 13C NMR (75 MHz,
CDCl3) d 13.6, 19.8, 29.4, 31.2, 39.6, 43.2, 45.8, 45.9, 50.6, 51.1, 57.4,
64.4, 66.1, 112.1, 119.1, 125.4, 126.8, 127.0, 127.5, 127.8, 128.0, 128.3,
128.8, 129.0, 135.4, 139.2, 141.2, 142.9, 153.2, 153.9, 154.5, 168.4,
170.4; 19F NMR (376 MHz, CDCl3) d75.10 (s, 3F, COCF3); HRMS (ESI)
calcd for C43H45F3N3O6 m/z 825.3087 (MþNa)þ, found 825.3050.
4.3.7. Methyl 2-(N-(2-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-4-
methylpentylamino)-2-oxoethyl)-2,2,2-triﬂuoroacetamido)-3-(4-
hydroxyphenyl)propanoate (4g). White solid; mp 183e184 C; Rf
0.46 (n-hexane/EtOAc, 2:1); RP-HPLC tR 23.9 (60e100% ACN;
30 min); [a]D20 68.5 (c 1.0, CHCl3); IR (KBr) nmax 3069, 2599, 1745,
1739, 1711, 1635, 1388 cm1; 1H NMR (300 MHz, CDCl3) d 0.94 [d,
J¼5.7 Hz, 6H, (CH3)2 Leu], 1.37e1.42 (m, 2H, CH2 Leu), 1.78 (m, 1H,
CH Leu), 3.08e3.18 (m, 2H, CH2 Tyr), 3.29e3.41 (m, 2H, CHCH2NH),
3.67 (s, 3H, OCH3), 3.96 (s, 2H, NHCOCH2N), 4.12 (m, 1H, CH Tyr),
4.42 (t, J¼4.9 Hz, 1H, CH Fmoc), 4.51 (br, 1H, OH Tyr), 4.68 (d,
J¼9.1 Hz, 2H, CH2 Fmoc), 4.76 (m,1H, CH Leu), 5.29 (br,1H, NH), 5.55
(br, 1H, NH), 7.01e7.78 (m, 13H, ArH); 13C NMR (75 MHz, CDCl3)
d 21.6, 22.5, 32.5, 41.5, 43.0, 46.1, 47.1, 49.5, 50.5, 51.3, 65.9, 112.5,
114.8, 127.2, 127.6, 128.0, 128.3, 129.0, 130.5, 141.2, 143.4, 154.5,
154.9, 170.2, 171.5; 19F NMR (376 MHz, CDCl3) d 74.51 (s, 3F,




triﬂuoroacetamido)acetate (4h). White solid; mp 129e130 C; Rf
0.51 (n-hexane/EtOAc, 2:1); RP-HPLC tR 24.4, 24.7 (60e100% ACN;
30 min); [a]D20 þ58.2 (c 1.0, CHCl3); IR (KBr) nmax 3089, 2586, 1750,
1745, 1710, 1631, 1388 cm1; 1H NMR (300 MHz, CDCl3) d 0.92 [d,
J¼4.8 Hz, 6H, (CH3)2 Val], 0.98 [s, 9H, (CH3)3 t-Bu], 2.12 (m, 1H, CH
Val), 3.09e3.19 (m, 2H, CHCH2NH), 3.98 (s, 2H, CH2 Gly), 4.11 (m,1H,
CH Val), 4.44 (t, J¼4.8 Hz, 1H, CH Fmoc), 4.51 (s, 1H, CH t-Bu), 4.62
(d, J¼6.1 Hz, 2H, CH2 Fmoc), 5.11 (s, 2H, OCH2Ph), 5.67 (br, 1H, NH),
5.98 (br, 1H, NH), 7.11e7.74 (m,13H, ArH); 13C NMR (75 MHz, CDCl3)
d 16.4, 23.9, 29.5, 31.4, 41.8, 44.1, 46.5, 57.0, 67.1, 67.9, 70.8, 112.2,
125.8, 126.2, 127.7, 127.9, 128.0, 128.3, 128.9, 139.5, 141.2, 143.0,
154.2, 155.2, 168.2, 170.4; 19F NMR (376 MHz, CDCl3) d75.05 (s, 3F,




acetamido)butanoate (4i). White solid; mp 111e113 C; Rf 0.47 (n-
N. Narendra et al. / Tetrahedron 68 (2012) 1992e20001998hexane/EtOAc, 2:1); RP-HPLC tR 20.4 (60e100% ACN; 30 min); [a]D20
24.4 (c 1.0, CHCl3); IR (KBr) nmax 3059, 2599,1755,1743,1711,1632,
1390 cm1; 1H NMR (300 MHz, CDCl3) d 1.12 (t, J¼4.5 Hz, 3H,
OCH2CH3), 1.92 (s, 3H, SCH3), 2.04e2.09 (m, 2H, CH2CH2SCH3), 2.17
(t, J¼3.1 Hz, 2H, CH2CH2SCH3), 2.28e2.37 (m, 2H, CH2 Asp),
3.12e3.22 (m, 2H, CHCH2NH), 4.01 (s, 2H, NHCOCH2N), 4.09 (m, 2H,
OCH2CH3), 4.28 (t, J¼6.8 Hz, 1H, CH Fmoc), 4.43 (t, J¼6.4 Hz, 1H, CH
Met), 4.61 (d, J¼8.6 Hz, 2H), 4.72 (m, 1H, CH Asp), 5.16 (s, 2H,
OCH2Ph), 5.67 (br, 1H, NH), 5.91 (br, 1H, NH), 7.08e7.79 (m, 13H,
HAr); 13C NMR (75 MHz, CDCl3) d 13.4, 16.1, 26.9, 29.2, 38.0, 41.2,
46.3, 49.9, 50.3, 58.7, 60.0, 66.5, 67.3, 112.0, 121.4, 125.8, 127.5, 127.9,
128.0, 128.5, 128.9, 139.4, 141.2, 143.6, 154.5, 154.9, 170.2, 170.9,
171.2; 19F NMR (376 MHz, CDCl3) d 74.79 (s, 3F, COCF3); HRMS




dimethylbutanamido)pentanoate (4j). White solid; mp 92e93 C; Rf
0.61 (n-hexane/EtOAc, 2:1); RP-HPLC tR 20.0, 20.4 (60e100% ACN;
30 min); [a]D20 8.4 (c 1.0, CHCl3); IR (KBr) nmax 3065, 2859, 1752,
1738, 1710, 1640, 1375 cm1; 1H NMR (300 MHz, CDCl3) d 0.92 [s,
9H, (CH3)3 t-Bu], 1.34 [s, 9H, O(CH3)3], 1.39 (d, J¼11.2 Hz, 3H, CH3
Ala), 1.73e1.79 (m, 2H, CH2CH2COO), 2.09 (t, J¼11.6 Hz, 2H,
CH2CH2COO), 3.12e3.19 (m, 2H, CHCH2NH), 3.96 (m, 1H, CH Ala),
4.42 (t, J¼5.6 Hz, 1H, CH Fmoc), 4.47 (m, 1H, CH t-Bu), 4.52 (m, 1H,
CH Glu), 4.68 (d, J¼3.9 Hz, 2H, CH2 Fmoc), 5.21 (s, 2H, OCH2Ph), 5.68
(br, 1H, NH), 6.15 (br, 1H, NH), 7.16e7.79 (m, 13H, ArH); 13C NMR
(75 MHz, CDCl3) d 13.8, 23.4, 26.5, 27.0, 27.9, 33.4, 44.5, 46.1, 46.9,
49.7, 66.9, 67.0, 68.5, 81.4, 112.8, 125.6, 126.4, 126.8, 127.8, 127.9,
128.2, 128.5, 139.8, 141.7, 143.2, 153.6, 154.0, 169.9, 170.2, 171.5; 19F
NMR (376 MHz, CDCl3) d75.29 (s, 3F, COCF3); HRMS (ESI) calcd for
C42H50F3N3O8 m/z 804.3448 (MþNa)þ, found 804.34421.
4.3.11. tert-Butyl 2-(N-(1-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-
3-methylpentylamino)-4-methyl-1-oxopentan-2-yl)-2,2,2-
triﬂuoroacetamido)propanoate (4k). White solid; mp 120e123 C;
Rf 0.63 (n-hexane/EtOAc, 2:1); RP-HPLC tR 20.0, 20.4 (60e100%
ACN; 30 min); [a]D20 þ120.8 (c 1.0, CHCl3); IR (KBr) nmax 3089, 2577,
1750, 1742, 1725, 1630,1390 cm1; 1H NMR (300 MHz, CDCl3) d 0.83
(t, J¼4.8 Hz, 3H, CH3CHCH2CH3 Ile), 0.94 [d, J¼5.6 Hz, 6H, (CH3)2 i-
Pr], 1.01 (d, J¼11.2 Hz, 3H, CH3CHCH2CH3 Ile), 1.11e1.19 (m, 2H, CH2
Ile), 1.32 [s, 9H, O(CH3)3], 1.41 (d, J¼5.4 Hz, 3H, CH3 Ala), 1.51e1.62
(m, 3H, CH2 i-Bu, CH i-Pr), 2.11 (m,1H, CHCH3 Ile), 3.12e3.19 (m ,2H,
CHCH2NH), 4.04 (m, 1H, CH Ile), 4.43 [m, 1H, CH(i-Bu)], 4.58e4.61
(m, 2H, CH Fmoc, CH Ala), 4.64 (d, J¼5.5 Hz, 2H, CH2, Fmoc), 5.55 (br,
1H, NH), 6.13 (br, 1H, NH), 7.21e7.85 (m, 8H, ArH); 13C NMR
(75 MHz, CDCl3) d 10.8, 14.0, 14.9, 21.4, 21.8, 24.6, 27.8, 37.6, 38.1,
41.1, 46.7, 47.0, 48.5, 55.0, 64.8, 81.4, 113.4, 126.7, 127.9, 128.4, 128.8,
139.8, 141.1, 143.2, 153.6, 154.0, 170.4, 171.1; 19F NMR (376 MHz,
CDCl3) d 75.69 (s, 3F, COCF3); HRMS (ESI) calcd for C36H48F3N3O6
m/z 698.3319 (MþNa)þ, found 698.3311.
4.4. General procedure for the synthesis of 5
Triﬂuoroacetamide Ugi product 4 (5.0 mmol) was dissolved in
MeOH (8.0 mL), p-TsOH$H2O (5.5 mmol,1.045 g) was added and the
resulting solution was reﬂuxed at 50 C for 30 min. The reaction
mixture was then cooled to room temperature, TEA (5.5 mmol,
0.56 mL) was added, and stirring was continued for another 5 min
to neutralize the tosylate salt. The solvent was removed in vacuo
and the residue was puriﬁed by column chromatography.
4.4.1. (2S)-Methyl 2-(2-(2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)eth-
ylamino)-2-oxo-1-phenylethylamino)-3-hydroxypropanoate(5a). White solid; mp 128e139 C; Rf 0.30 (CHCl3/MeOH, 8:2); RP-
HPLC tR 8.2, 8.8 (60e100% ACN; 30 min); [a]D20 þ3.8 (c 1.0, CHCl3);
IR (KBr) nmax 3054, 2875,1741, 1738,1659, 1588, 1390 cm1; 1H NMR
(300 MHz, CDCl3) d 2.98 (br, 1H, OH Ser), 3.26e3.32 (m, 2H,
NHCH2CH2), 3.41e3.49 (m, 2H, NHCH2CH2), 3.57 (m, 1H, CH Ser),
3.71 (s, 3H, OCH3), 3.86 (m, 1H, CH2 Ser), 4.00 (m, 1H, CH2 Ser), 4.43
(t, J¼7.2 Hz,1H, CH Fmoc), 4.65 (d, J¼8.6 Hz, 2H, CH2 Fmoc), 4.88 (m,
1H, CH(Ph)), 5.92 (br, 1H, NH), 6.68 (br, 2H, NH), 7.06e7.76 (m, 13H,
ArH); 13C NMR (75 MHz, CDCl3) d 42.1, 43.4, 46.6, 52.3, 60.0, 62.4,
66.9, 72.1, 126.3, 126.9, 128.2, 128.4, 128.7, 129.2, 129.5, 135.5, 141.2,
143.6, 155.8, 169.9, 170.7; HRMS (ESI) calcd for C29H31N3O6 m/z
540.2111 (MþNa)þ, found 540.2118.
4.4.2. (S)-Ethyl 2-(2-((S)-2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)pro-
pylamino)-2-oxoethylamino)-3-phenylpropanoate (5b). White solid;
mp 141e143 C; Rf 0.18 (CHCl3/MeOH, 8:2); RP-HPLC tR 7.5 (60e100%
ACN; 30 min); [a]D20 18.6 (c 1.0, CHCl3); IR (KBr) nmax 3050, 2864,
1740, 1735, 1631, 1511, 1384 cm1; 1H NMR (300 MHz, CDCl3) d 1.28
(m, 6H, CH3 Ala, OCH2CH3), 2.92 (m, 1H, CH2 Phe), 3.12 (m, 1H, CH2
Phe), 3.29 (m, 1H, CHCH2NH), 3.38e3.44 (m, 4H, CHCH2NH,
COCH2NH), 3.69 (m,1H, CH Phe), 4.03 (m, 2H, OCH2CH3), 4.21 (m,1H,
CH Ala), 4.44 (t, J¼7.4 Hz, 1H, CH Fmoc), 4.68 (d, J¼8.6 Hz, 2H, CH2
Fmoc), 5.81 (br, 1H, NH), 6.73 (br, 2H, NH), 7.06e7.78 (m, 13H, ArH);
13C NMR (75 MHz, CDCl3) d 13.3, 17.8, 35.2, 45.3, 46.1, 46.9, 48.7, 57.3,
59.2, 66.4, 125.8, 126.3, 126.9, 127.3, 127.6, 127.9, 128.4, 139.8, 140.9,




anoate (5c). White solid; mp 158e160 C; Rf 0.18 (CHCl3/MeOH,
8:2); RP-HPLC tR 9.8, 10.4 (60e100% ACN; 30 min); [a]D20 þ113.2 (c
1.0, CHCl3); IR (KBr) nmax 3040, 2898, 1758, 1721, 1641, 1575,
1388 cm1; 1H NMR (300 MHz, CDCl3) d 0.98 [d, J¼5.6 Hz, 6H,
CH(CH3)2], 1.24 (d, J¼6.8 Hz, 3H, CH3 Ala), 1.57 [m, 2H,
CH2CH(CH3)2], 1.78 [m, 1H, CH2CH(CH3)2], 2.92 (m, 1H, CH2 Phe),
3.03 (m, 1H, CH2 Phe), 3.21 (m, 1H, CHCH2), 3.37 (m, 1H, CHCH2),
3.58e3.68 (m, 2H, CH i-Bu, CH Ala), 3.71 (s, 3H, OCH3), 4.41 (t,
J¼7.7 Hz, 1H, CH Fmoc), 4.52 (m, 1H, CH Phe), 4.67 (d, J¼8.1 Hz, 2H,
CH2 Fmoc), 5.78 (br, 2H, NH), 6.41 (br, 1H, NH), 7.08e7.81 (m, 13H,
ArH); 13C NMR (75 MHz, CDCl3) d 16.8, 19.2, 20.1, 38.6, 39.6, 42.3,
46.2, 52.1, 52.8, 53.9, 55.7, 66.3, 125.3, 126.4, 127.8, 128.1, 128.5,
128.9, 136.2, 140.2, 143.1, 156.3, 170.2, 170.8; HRMS (ESI) calcd for
C34H41N3O5 m/z 594.2944 (MþNa)þ, found 594.2946.
4.4.4. (S)-(9H-Fluoren-9-yl)methyl 2-((2-((S)-1-(benzyloxy)-3-
methyl-1-oxobutan-2-ylamino)acetamido)methyl)pyrrolidine-1-
carboxylate (5d). Pale yellow solid; mp 109e111 C; Rf 0.21 (CHCl3/
MeOH, 8:2); RP-HPLC tR 6.9 (60e100% ACN; 30 min); [a]D20 89.4 (c
1.0, CHCl3); IR (KBr) nmax 3048, 2879, 1740, 1731, 1660, 1551,
1386 cm1; 1H NMR (300 MHz, CDCl3) 0.98 [d, J¼5.2 Hz, 6H, (CH3)2
Val], 1.28e1.60 (m, 4H, NCH2CH2CH2 Pro), 2.56 (m, 1H, CH(CH3)2
Val), 3.28e3.49 (m, 7H, NCH2 Pro, NCHCH2 Pro, COCH2NH, CH Val),
3.80 (m, 1H, NCH Pro), 4.41 (t, J¼7.1 Hz, 1H, CH Fmoc), 4.68 (d,
J¼8.8 Hz, 2H, CH2 Fmoc), 5.12 (s, 2H, OCH2Ph), 6.32 (br, 1H, NH),
6.79 (br, 1H, NH), 7.16 (s, 5H, ArH), 7.31e7.83 (m, 8H, ArH); 13C NMR
(75 MHz, CDCl3) d 16.4, 21.0, 26.2, 29.8, 42.1, 46.3, 47.2, 49.8, 55.2,
59.8, 64.2, 66.9, 126.4, 126.9, 127.2, 127.5, 128.0, 128.2, 128.6, 141.0,
141.6, 143.2,155.8,169.9, 170.3; HRMS (ESI) calcd for C34H39N3O5m/
z 592.2787 (MþNa)þ, found 592.2796.
4.4.5. (S)-Methyl 2-(2-((S)-2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-
3-phenylpropylamino)-2-oxo-1-phenylethylamino)propanoate
(5e). Pale yellow solid; mp 135e137 C; Rf 0.41 (CHCl3/MeOH, 8:2);
RP-HPLC: tR 11.2, 11.5 (60e100% ACN; 30 min); [a]D20 þ69.8 (c 1.0,
N. Narendra et al. / Tetrahedron 68 (2012) 1992e2000 1999CHCl3); IR (KBr) nmax 3048, 2881, 1742, 1736, 1660, 1581, 1380 cm1;
1H NMR (300 MHz, CDCl3) d 1.19 (d, J¼8.6 Hz, 3H, CH3 Ala), 2.92 (m,
1H, CH2 Phe), 3.03 (m, 1H, CH2 Phe), 3.26 (m, 2H, CHCH2NH),
3.34e3.42 (m, 2H, CHCH2NH, CH Ala), 3.68 (s, 3H, OCH3), 4.41 (t,
J¼7.9 Hz, 1H, CH Fmoc), 4.58 (m, 1H, CH Phe), 4.67 (d, J¼6.8 Hz, 2H,
CH2 Fmoc), 4.71 (s, 1H, CH Ph), 5.98 (br, 2H, NH), 6.63 (br, 1H, NH),
7.04e7.80 (m, 18H, ArH); 13C NMR (75 MHz, CDCl3) d 16.4, 39.6,
42.4, 44.8, 52.1, 52.9, 53.7, 6.09, 66.7, 126.0, 126.4, 127.4, 127.6, 127.8,
128.2, 128.3, 128.4, 128.6, 128.8, 138.2, 139.6, 140.8, 143.1, 155.6,




anoate (5f). White solid; mp 171e173 C; Rf 0.17 (CHCl3/MeOH,
8:2); RP-HPLC tR 5.6, 5.9 (60e100% ACN; 30 min); [a]D20 109.7 (c
1.0, CHCl3); IR (KBr) nmax 3051, 2870, 1739, 1735, 1655, 1589,
1390 cm1; 1H NMR (300 MHz, CDCl3) d 1.26 (d, J¼5.5 Hz, 3H, CH3
Ala) 1.28e1.45 [m, 6H, NHCH2(CH2)3 Lys], 2.44 [m, 2H,
NHCH2(CH2)3 Lys], 3.26 (m, 1H, NHCHCH2NH), 3.59 (m, 2H,
NHCHCH2NH, CH Ala), 3.69 (s, 3H, OCH3), 4.44 (m, 2H, CH Fmoc, CH
Lys) 4.65 (d, J¼7.0 Hz, 2H, CH2 Fmoc), 4.78 (m, 1H, CH Ph), 5.08 (s,
2H, CH2 Z), 5.74 (br, 2H, NH), 6.64 (br, 1H, NH), 7.08e7.79 (m, 18H,
ArH); 13C NMR (75 MHz, CDCl3) d 16.9, 20.2, 27.7, 29.1, 40.3, 46.5,
47.2, 47.8, 52.3, 54.3, 59.6, 61.2, 66.8, 119.7, 124.9, 125.3, 126.8, 127.5,
127.7,127.9,128.3,128.9,129.4,139.2,140.2,141.1,143.6,155.7,156.4,




anoate (5g). White solid; mp 166e168 C; Rf 0.11 (CHCl3/MeOH,
8:2); RP-HPLC: tR 5.2 (60e100% ACN; 30 min); [a]D20 29.4 (c 1.0,
CHCl3); IR (KBr) nmax 3038, 2868,1742, 1736, 1655, 1538, 1394 cm1;
1H NMR (300 MHz, CDCl3) d 0.98 [d, J¼4.2 Hz, 6H, (CH3)2 Leu], 1.37
(m, 2H, CH2 Leu),1.76 (m,1H, CH Leu), 2.97 (m,1H, CH2 Tyr), 3.13 (m,
1H, CH2 Tyr), 3.28 (m, 1H, CHCH2NH), 3.41 (s, 2H, COCH2NH), 3.47
(m,1H, CHCH2NH), 3.71 (s, 3H, OCH3), 3.79 (m,1H, CH Tyr), 3.99 (m,
1H, CH Leu), 4.43 (t, J¼7.0 Hz, 1H, CH Fmoc), 4.68 (d, J¼78.1 Hz, 2H,
CH2 Fmoc), 4.98 (br, 1H, OH Tyr), 5.97 (br, 2H, NH), 6.61 (br, 1H, NH),
6.76 (d, J¼7.2 Hz, 2H, ArH), 6.93 (d, J¼7.1 Hz, 2H, ArH), 7.31e7.79 (m,
8H, ArH); 13C NMR (75 MHz, CDCl3) d 21.7, 22.6, 35.3, 40.7, 42.1, 46.2,
47.4, 49.6, 52.1, 58.3, 65.4, 115.6, 126.6, 128.0, 128.2, 128.7, 129.0,
131.2, 141.1, 143.2, 155.9, 156.3, 170.3, 173.8; HRMS calcd for
C33H39N3O6 m/z 596.2737 (MþNa)þ, found 596.2748.
4.4.8. Benzyl 2-(1-((S)-2-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-3-
methylbutylamino)-3,3-dimethyl-1-oxobutan-2-ylamino)acetate
(5h). White solid; mp 98e100 C; Rf 0.46 (CHCl3/MeOH, 8:2); RP-
HPLC tR 12.4, 12.9 (60e100% ACN; 30 min); [a]D20 þ74.5 (c 1.0,
CHCl3); IR (KBr) nmax 3048, 2868, 1745, 1740, 1664, 1579, 1389 cm1;
1H NMR (300 MHz, CDCl3) d 0.98 [d, J¼4.8 Hz, 6H, (CH3)2 Val], 1.08
[s, 9H, (CH3)3 t-Bu], 2.38 (m, 1H, CH Val), 3.22 (m, 1H, CHCH2NH),
3.37e3.50 (m, 4H, CHCH2NH, CH t-Bu, CH2 Gly), 4.18 (m,1H, CH Val),
4.41 (t, J¼7.0 Hz, 1H, CH Fmoc), 4.68 (d, J¼7.5 Hz, 2H, CH2 Fmoc),
5.12 (s, 2H, OCH2Ph), 5.49 (br, 1H, NH), 6.18 (br, 2H, NH), 7.15 (s, 5H,
HAr), 7.26e7.35 (m, 4H, ArH), 7.54 (d, J¼6.9 Hz, 2H, ArH), 7.76 (d,
J¼7.0 Hz, 2H, ArH); 13C NMR (75 MHz, CDCl3) d 16.3, 23.8, 29.6, 35.2,
42.3, 46.8, 47.1, 57.8, 66.1, 67.3, 74.8, 126.2, 126.8, 127.3, 127.6, 128.0,
128.4, 128.8, 141.0, 141.3, 143.5, 155.6, 169.3, 170.1; HRMS (ESI) calcd
for C35H43N3O5 m/z 608.3100 (MþNa)þ, found 608.3113.
4.4.9. (S) Benzyl-3-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-4-(2-((S)-
1-methoxy-4-(methylthio)-1-oxobutan-2-ylamino)acetamido)buta-
noate (5i). Pale yellow solid; mp 113e115 C; Rf 0.58 (CHCl3/MeOH,
8:2); RP-HPLC tR 13.1, 13.8 (60e100% ACN; 30 min); [a]D20 þ28.9 (c1.0, CHCl3); IR (KBr) nmax 3048, 2865, 1745, 1740, 1732, 1654, 1555,
1380 cm1; 1H NMR (300 MHz, CDCl3) d 1.27 (t, J¼6.6 Hz, 3H,
OCH2CH3), 2.01 (s, 3H, SCH3), 2.12 (m, 2H, CH2CH2SCH3), 2.38 (m,
3H, CH2CH2SCH3, CH2 Asp), 2.51 (m,1H, CH2 Asp), 3.32e3.51 (m, 5H,
CHCH2NH, COCH2NH, CH Met), 4.09 (m, 2H, OCH2CH3), 4.44 (t,
J¼7.0 Hz, 1H, CH Fmoc), 4.67 (d, J¼8.2 Hz, 2H, CH2 Fmoc), 4.74 (m,
1H, CH Asp), 5.10 (s, 2H, OCH2Ph), 5.71 (br, 1H, NH), 5.96 (br, 1H,
NH), 6.43 (br, 1H, NH), 7.16 (s, 5H, ArH), 7.25e7.78 (m, 8H, ArH); 13C
NMR (75 MHz, CDCl3) d 13.8, 16.9, 29.8, 31.0, 38.4, 44.2, 46.3, 50.2,
51.1, 57.9, 59.8, 66.9, 67.5, 126.5, 126.9, 127.4, 127.9, 128.2, 128.6,
128.9, 141.0, 141.3, 143.5, 155.8, 169.8, 170.1, 172.3; HRMS calcd for
C35H41N3O7S m/z 670.2563 (MþNa)þ, found 670.2571.
4.4.10. (S)-Benzyl 4-(((9H-ﬂuoren-9-yl)methoxy)carbonyl)-5-(2-((S)-
1-tert-butoxy-1-oxopropan-2-ylamino)-3,3-dimethylbutanamido)
pentanoate (5j). White solid; mp 160e162 C; Rf 0.55 (CHCl3/
MeOH, 8:2); RP-HPLC tR 9.1, 9.7 (60e100% ACN; 30 min); [a]D20
24.4 (c 1.0, CHCl3); IR (KBr) nmax 3051, 2855, 1751, 1745, 1738, 1655,
1540, 1369 cm1; 1H NMR (CDCl3, 300 MHz) d 1.01 [s, 9H, (CH3)3 t-
Bu],1.23 (d, J¼6.8 Hz, 3H, CH3 Ala),1.38 [s, 9H, O(CH3)3], 1.78 (m, 2H,
CH2CH2COO), 2.13 (t, J¼6.1 Hz, 2H, CH2CH2COO), 3.23 (m, 1H,
CHCH2NH), 3.29 (m, 1H, CHCH2NH), 3.61 (s, 1H, CH t-Bu), 3.74 (m,
1H, CH Ala), 4.36 (m, 1H, CH Glu), 4.42 (t, J¼6.4 Hz, 1H, CH Fmoc),
4.65 (d, J¼8.0 Hz, 2H, CH2 Fmoc), 5.14 (s, 2H, OCH2Ph), 5.92 (br, 1H,
NH), 6.73 (br, 2H, NH), 7.13 (s, 5H, ArH), 7.23e7.35 (m, 4H, ArH), 7.51
(d, J¼7.1 Hz, 2H, HAr), 7.75 (d, J¼7.2 Hz, 2H, ArH); 13C NMR (CDCl3,
75 MHz) d 16.8, 23.8, 25.3, 26.7, 28.9, 36.2, 43.8, 45.7, 49.3, 55.1,
65.6, 67.4, 73.6, 81.2, 126.2, 126.9, 127.2, 127.7, 128.1, 128.4, 128.8,
140.8, 141.2, 143.0, 155.4, 169.2, 170.3, 170.5; HRMS (ESI) calcd for
C40H51N3O7 m/z 708.3625 (MþNa)þ, found 708.3629.
4.4.11. (S)-tert-Butyl 2-(1-((2S,3S)-2-(((9H-ﬂuoren-9-yl)methoxy)car-
bonyl)-3-methylpentylamino)-4-methyl-1-oxopentan-2-ylamino)
propanoate (5k). White solid; mp 125e127 C; Rf 0.47 (CHCl3/MeOH,
8:2); RP-HPLC tR 8.6, 8.9 (60e100% ACN; 30 min); [a]D20 22.0 (c 1.0,
CHCl3); IR (KBr) nmax 3048, 2849, 1742, 1740, 1738, 1661, 1538,
1355 cm1; 1H NMR (CDCl3, 300 MHz) d 0.89e1.01 [m, 12H,
CH3CHCH2CH3 Ile, (CH3)2 i-Pr], 1.31 (m, 5H, CH3 Ala, CH2 Ile), 1.37 [s,
9H, O(CH3)3],1.49 (m, 2H, CH2 i-Bu),1.71 (m,1H, CH i-Pr), 2.13 (m,1H,
CHCH3 Ile), 3.27 (m,1H, CHCH2NH), 3.32 (m,1H, CHCH2NH), 3.58 [m,
1H, CH(i-Bu)], 3.74 (m, 1H, CH Ala), 4.33 (m, 1H, CH Ile), 4.43 (t,
J¼6.6 Hz, 1H, CH Fmoc), 4.63 (d, J¼8.2 Hz, 2H, CH2 Fmoc), 5.67 (br,
1H, NH), 6.69 (br, 2H, NH), 7.21e7.32 (m, 4H, ArH), 7.50 (d, J¼7.0 Hz,
2H, ArH), 7.78 (d, J¼7.0 Hz, 2H, ArH); 13C NMR (CDCl3, 75 MHz)
d 12.3, 14.6, 16.7, 21.4, 23.2, 26.4, 29.1, 37.3, 40.9, 42.1, 48.6, 56.2, 56.4,
58.1, 66.3, 81.8, 125.4, 126.3, 126.7, 127.2, 141.2, 143.4, 155.7, 169.3,
170.2; HRMS (ESI) calcd for C34H49N3O5 m/z 602.3570 (MþNa)þ,
found 602.3573.
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